In this issue:
- Disparities in immunotherapy use for triple-negative breast cancer
- Efficacy and safety of ICIs in elderly patients with advanced NSCLC
- OS better in NSCLC when immunochemotherapy is administered in the morning
- Nivolumab-ipilimumab in microsatellite-instability-high metastatic colorectal cancer
- Burden and clinical trajectory of ICI-induced endocrinopathies
- First-line chemotherapy ± ICI for advanced gastric cancer
- Nervous system events associated with blinatumomab
- Induced pluripotent stem-cell-derived CD19-directed CAR NK cells for B-cell lymphoma
- 10-year outcomes for nivolumab-ipilimumab in advanced melanoma
- Talquetamab-teclistamab for relapsed/refractory multiple myeloma
Please login below to download this issue (PDF)